z-logo
open-access-imgOpen Access
Revisiting the Role of Neutralizing Antibodies in Mother‐to‐Child Transmission of HIV‐1
Author(s) -
Françis Barin,
Gonzague Jourdain,
S. Brunet,
Nicole NgoGiangHuong,
Supawadee Weerawatgoompa,
Warit Karnchanamayul,
Surabhon Ariyadej,
Rawiwan Hansudewechakul,
Jullapong Achalapong,
Prapap Yuthavisuthi,
Chaiwat Ngampiyaskul,
Sorakij Bhakeecheep,
Chittaphon Hemwutthiphan,
Marc Lallemant
Publication year - 2006
Publication title -
the journal of infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.69
H-Index - 252
eISSN - 1537-6613
pISSN - 0022-1899
DOI - 10.1086/503778
Subject(s) - neutralizing antibody , virology , heterologous , antibody , transmission (telecommunications) , immunology , medicine , lentivirus , zidovudine , viral load , titer , biology , virus , viral disease , genetics , electrical engineering , gene , engineering
We analyzed the association between mother-to-child transmission (MTCT) of human immunodeficiency virus type 1 (HIV-1) and maternal neutralizing antibodies to heterologous primary isolates of various HIV-1 clades, to test the hypothesis that protective antibodies are those with broad neutralizing activity. Our study sample included 90 Thai women for whom the timing of HIV-1 transmission (in utero or intrapartum) was known. The statistical analysis included a conditional logistic-regression model to control for both plasma viral load and duration of zidovudine prophylaxis. The higher the titer of neutralizing antibodies to a heterologous strain of the same clade, the lower the rate of MTCT of HIV-1. More specifically, high levels of neutralizing antibodies to the MBA (CRF01_AE) strain were associated with low intrapartum transmission of HIV-1. This suggested that such heterologous neutralizing antibodies may be involved in the natural prevention of late perinatal HIV transmission. These data are consistent with the hypothesis that the use of some antibodies might help to prevent perinatal HIV transmission, through passive immunoprophylaxis. Moreover, the study of humoral factors associated with MTCT of HIV-1 may identify correlates of protection that should help in the design of efficient HIV/acquired immunodeficiency syndrome vaccines.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom